Getting Doctors and Technologists to Talk About Artificial Intelligence

On the occasion of the Artificial Intelligence Appreciation Day, a conference will be held at the Champalimaud Foundation aimed at bridging the gap between AI innovation and its implementation in medical practice.

The goal of the MEDICA AI - The Conference, which will take place on July 16 at the Champalimaud Foundation (FC), is to familiarise healthcare professionals, with the latest AI tools so that they can apply them in their daily practice for the benefit of patients.

The images created during the daily scientific and medical endeavours at the Champalimaud Foundation can be as beautiful and compelling as any work of art. To the untrained eye, these images might also appear baffling, but, if you know what you’re looking at, they may just reveal information that can spark discoveries, contribute to the improvement of patient quality of life and maybe even alter our understanding of reality.

The images created during the daily scientific and medical endeavours at the Champalimaud Foundation can be as beautiful and compelling as any work of art. To the untrained eye, these images might also appear baffling, but, if you know what you’re looking at, they may just reveal information that can spark discoveries, contribute to the improvement of patient quality of life and maybe even alter our understanding of reality.

Join us for the FAITH Project's closing conference, where we'll delve into the crucial intersection of the FAITH AI technology and trials as well as key issues of mental health, survivorship in cancer and lessons learnt.

Meeting Description

This meeting collaboration between the Association for Cancer Immunotherapy CIMT and the Champalimaud Foundation will address promising paths towards effective cellular treatment modalities for patients with solid cancer and discuss the boundaries of synthetically engineered immune cells. The meeting will also discuss the innovation gap between academic and small biotech driven research, and the challenges of safe, biologically, and clinically relevant phase I / II clinical trials. 

Description

Nuno Prego Ramos, co-founder and CEO of CellmAbs, will share the journey of CellmAbs, from it's early days starting with an initial technology from NOVA University to becoming a pioneering force in cancer therapy innovation.

In this talk, we will hear about the strategic decisions, challenges and breakthroughs that propelled the company to its selling the assets to the pharmaceutical giant, BioNTech.

“When I explain to my friends and family the rigorous regulations in place to ensure ethical treatment of experimental animals, they seem surprised.
 
It is important that people know that researchers that use animals are obliged to have appropriate qualifications and training. That scientific projects are evaluated to ensure that the use of animals is needed, beneficial and that no unnecessary harm is inflicted. And that the highest standards of housing conditions must be provided by the facilities where animals are housed.
 

Reported today in Science, the researchers found that mice given a diet rich in vitamin D had better immune resistance to experimentally transplanted cancers and improved responses to immunotherapy treatment. This effect was also seen when gene editing was used to remove a protein that binds to vitamin D in the blood and keeps it away from tissues.

Host

Carlos Minutti, Principal Investigator, Champalimaud Research

Venue

Seminar room